RMD
Price
$244.99
Change
-$1.23 (-0.50%)
Updated
Nov 19 closing price
Capitalization
35.76B
63 days until earnings call
Intraday BUY SELL Signals
RSMDF
Price
$24.64
Change
+$0.64 (+2.67%)
Updated
Nov 19 closing price
Capitalization
35.76B
63 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

RMD vs RSMDF

Header iconRMD vs RSMDF Comparison
Open Charts RMD vs RSMDFBanner chart's image
ResMed
Price$244.99
Change-$1.23 (-0.50%)
Volume$942.85K
Capitalization35.76B
Resmed
Price$24.64
Change+$0.64 (+2.67%)
Volume$382
Capitalization35.76B
RMD vs RSMDF Comparison Chart in %
RMD
Daily Signal:
Gain/Loss:
RSMDF
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
RMD vs. RSMDF commentary
Nov 20, 2025

To understand the difference between Resmed Inc. (RMD) vs. Resmed Inc. - Chess Depository Interest (RSMDF) it is enough to know the definitions of Chess Depository Interest

Chess Depository Interest - Chess Depositary Interest (CDI) is the instrument developed by a subsidiary of the Australian Securities Exchange (ASX) that gives investors the same beneficial interests in foreign companies and funds as holding these shares and funds directly on their foreign exchange. CDIs investors receive W8-BEN and leverage the Australia-US tax treaty to reduce withholding tax on foreign income.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 20, 2025
Stock price -- (RMD: $244.99 vs. RSMDF: $24.64)
Brand notoriety: RMD and RSMDF are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: RMD: 87% vs. RSMDF: 3%
Market capitalization -- RMD: $35.76B vs. RSMDF: $35.76B
RMD [@Pharmaceuticals: Other] is valued at $35.76B. RSMDF’s [@Pharmaceuticals: Other] market capitalization is $35.76B. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $200.16B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $11.66B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

RMD’s FA Score shows that 0 FA rating(s) are green whileRSMDF’s FA Score has 0 green FA rating(s).

  • RMD’s FA Score: 0 green, 5 red.
  • RSMDF’s FA Score: 0 green, 5 red.
According to our system of comparison, RSMDF is a better buy in the long-term than RMD.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RMD’s TA Score shows that 6 TA indicator(s) are bullish while RSMDF’s TA Score has 2 bullish TA indicator(s).

  • RMD’s TA Score: 6 bullish, 2 bearish.
  • RSMDF’s TA Score: 2 bullish, 8 bearish.
According to our system of comparison, RMD is a better buy in the short-term than RSMDF.

Price Growth

RMD (@Pharmaceuticals: Other) experienced а -2.88% price change this week, while RSMDF (@Pharmaceuticals: Other) price change was -3.52% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -2.03%. For the same industry, the average monthly price growth was -0.29%, and the average quarterly price growth was +8.18%.

Reported Earning Dates

RMD is expected to report earnings on Jan 22, 2026.

RSMDF is expected to report earnings on Jan 22, 2026.

Industries' Descriptions

@Pharmaceuticals: Other (-2.03% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RMD($35.8B) and RSMDF($35.8B) have the same market capitalization . RSMDF (25.22) and RMD (25.08) have similar P/E ratio . RSMDF YTD gains are higher at: 8.721 vs. RMD (8.082). RMD (2B) and RSMDF (2B) have comparable annual earnings (EBITDA) . RMD (846M) and RSMDF (846M) have identical debt. RMD (5.26B) and RSMDF (5.26B) have equivalent revenues.
RMDRSMDFRMD / RSMDF
Capitalization35.8B35.8B100%
EBITDA2B2B100%
Gain YTD8.0828.72193%
P/E Ratio25.0825.2299%
Revenue5.26B5.26B100%
Total CashN/AN/A-
Total Debt846M846M100%
FUNDAMENTALS RATINGS
RMD vs RSMDF: Fundamental Ratings
RMD
RSMDF
OUTLOOK RATING
1..100
450
VALUATION
overvalued / fair valued / undervalued
1..100
35
Fair valued
36
Fair valued
PROFIT vs RISK RATING
1..100
6875
SMR RATING
1..100
3737
PRICE GROWTH RATING
1..100
6142
P/E GROWTH RATING
1..100
6963
SEASONALITY SCORE
1..100
5075

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RMD's Valuation (35) in the Medical Specialties industry is in the same range as RSMDF (36) in the null industry. This means that RMD’s stock grew similarly to RSMDF’s over the last 12 months.

RMD's Profit vs Risk Rating (68) in the Medical Specialties industry is in the same range as RSMDF (75) in the null industry. This means that RMD’s stock grew similarly to RSMDF’s over the last 12 months.

RMD's SMR Rating (37) in the Medical Specialties industry is in the same range as RSMDF (37) in the null industry. This means that RMD’s stock grew similarly to RSMDF’s over the last 12 months.

RSMDF's Price Growth Rating (42) in the null industry is in the same range as RMD (61) in the Medical Specialties industry. This means that RSMDF’s stock grew similarly to RMD’s over the last 12 months.

RSMDF's P/E Growth Rating (63) in the null industry is in the same range as RMD (69) in the Medical Specialties industry. This means that RSMDF’s stock grew similarly to RMD’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
RMDRSMDF
RSI
ODDS (%)
Bullish Trend 1 day ago
63%
Bearish Trend 1 day ago
37%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
71%
Bearish Trend 1 day ago
26%
Momentum
ODDS (%)
Bullish Trend 1 day ago
63%
Bearish Trend 1 day ago
32%
MACD
ODDS (%)
Bullish Trend 1 day ago
62%
Bearish Trend 1 day ago
26%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
58%
Bearish Trend 1 day ago
40%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
53%
Bearish Trend 1 day ago
34%
Advances
ODDS (%)
Bullish Trend 3 days ago
61%
Bullish Trend 9 days ago
25%
Declines
ODDS (%)
Bearish Trend 7 days ago
59%
Bearish Trend 18 days ago
67%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
70%
Bearish Trend 1 day ago
21%
Aroon
ODDS (%)
Bearish Trend 1 day ago
53%
Bearish Trend 1 day ago
32%
View a ticker or compare two or three
Interact to see
Advertisement
RMD
Daily Signal:
Gain/Loss:
RSMDF
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
NYAX43.353.52
+8.84%
Nayax Ltd
LCCCU10.35N/A
N/A
Lakeshore Acquisition III Corp
AGCO101.21-0.89
-0.87%
AGCO Corp
EPRX6.21-0.16
-2.51%
Eupraxia Pharmaceuticals
GNTA1.79-0.20
-10.05%
Genenta Science SpA

RMD and

Correlation & Price change

A.I.dvisor indicates that over the last year, RMD has been loosely correlated with SOLV. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if RMD jumps, then SOLV could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RMD
1D Price
Change %
RMD100%
-0.50%
SOLV - RMD
51%
Loosely correlated
+0.55%
NVST - RMD
45%
Loosely correlated
-0.94%
BLCO - RMD
43%
Loosely correlated
-3.18%
RVTY - RMD
40%
Loosely correlated
-0.87%
SYK - RMD
39%
Loosely correlated
+1.31%
More

RSMDF and

Correlation & Price change

A.I.dvisor tells us that RSMDF and NAOV have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that RSMDF and NAOV's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RSMDF
1D Price
Change %
RSMDF100%
+2.67%
NAOV - RSMDF
30%
Poorly correlated
-9.95%
RMD - RSMDF
20%
Poorly correlated
-0.50%
PFGTF - RSMDF
19%
Poorly correlated
N/A
POSC - RSMDF
9%
Poorly correlated
+1.71%
SAFLF - RSMDF
9%
Poorly correlated
N/A
More